{"id":25853,"date":"2023-10-04T13:04:49","date_gmt":"2023-10-04T07:34:49","guid":{"rendered":"https:\/\/blog.researchandranking.com\/?p=25853"},"modified":"2025-11-10T13:31:33","modified_gmt":"2025-11-10T08:01:33","slug":"valiant-laboratories-ipo-subscription-status-listing-allotment-date","status":"publish","type":"post","link":"https:\/\/www.equentis.com\/blog\/valiant-laboratories-ipo-subscription-status-listing-allotment-date\/","title":{"rendered":"Valiant Laboratories IPO &#8211; Subscription Status, Allotment &#038; Other Key Dates"},"content":{"rendered":"<div id=\"bsf_rt_marker\"><\/div><div class=\"wp-block-post-date\"><time datetime=\"2023-10-04T13:04:49+05:30\">October 4, 2023<\/time><\/div>\n\n\n<p>Recently, Valiant Laboratories, a prominent Indian pharmaceutical ingredient manufacturer, made its foray into the world of Initial Public Offerings (IPOs). From September 27 to October 3, 2023, the IPO attracted a frenzy of investor interest, and the subscription rate reached a staggering 29.76 times the number of shares on offer by the final day.<\/p>\n\n\n\n<p>Interestingly, Valiant Laboratories has experienced consistent revenue growth in recent years. The company\u2019s <a class=\"wpil_keyword_link\" href=\"https:\/\/www.equentis.com\/ipos\" title=\"IPO\" link=\"linked\" id=\"254\">IPO<\/a>, which was open for subscription from September 27, was priced at a band of \u20b9133 to \u20b9140 per equity share for the public offering.<\/p>\n\n\n\n<p><strong>The distribution of shares in the <a class=\"wpil_keyword_link\" href=\"https:\/\/www.equentis.com\/ipos\" title=\"IPO\" link=\"linked\" id=\"322\">IPO<\/a> was divided as follows:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Qualified Institutional Buyers (QIBs) &#8211; up to 50%<\/li>\n\n\n\n<li>Non-Institutional Investors (NIIs) &#8211; at least 15%<\/li>\n\n\n\n<li>Retail Investors &#8211; a minimum of 35%<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Valiant Laboratories IPO Subscription Status<\/h2>\n\n\n\n<p>As the days progressed, the subscription status kept investors on the edge. Retail investors displayed remarkable enthusiasm on the fourth day, subscribing to their portion 16.06 times. Meanwhile, Non-Institutional Investors (NIIs) exhibited extraordinary interest by subscribing a whopping 73.64 times, and Qualified Institutional Buyers (QIBs) followed closely behind, oversubscribing their portion by 20.83 times.<\/p>\n\n\n\n<p>Here is a brief overview of Valiant Laboratories <a class=\"wpil_keyword_link\" href=\"https:\/\/www.equentis.com\/ipos\" title=\"IPO\" link=\"linked\" id=\"599\">IPO<\/a> subscription status throughout its offering:<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter is-resized\"><img decoding=\"async\" src=\"https:\/\/lh6.googleusercontent.com\/Z-aFur6G6hFkAYhGeIPmzlhsJ2CAnwrBtnAOO8J1YGQWOa0ycw8NGC3WHMsAM9qh9QSK1lEuil3JpkC19gJFqeZxo8o2zsH3oGbTVq7B2XjUTt9azOk2uUkuPgtfFwP4Hb_br6DL1I4f5Yf5Y5uVYq0\" alt=\"\" style=\"width:618px;height:270px\" title=\"\"><figcaption class=\"wp-element-caption\">Source: Mint<\/figcaption><\/figure>\n\n\n\n<p>With such robust demand, it\u2019s clear that Valiant Laboratories\u2019 <a class=\"wpil_keyword_link\" href=\"https:\/\/www.equentis.com\/ipos\" title=\"IPO\" link=\"linked\" id=\"923\">IPO<\/a> has captured the market\u2019s attention and investor confidence.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Valiant Laboratories IPO Allotment &amp; Listing Date <\/h2>\n\n\n\n<p>For those eagerly awaiting their allotment, the schedule is as follows:<\/p>\n\n\n\n<figure class=\"wp-block-table aligncenter is-style-regular\"><table><tbody><tr><td>Basis for Allotment<\/td><td>October 5<\/td><\/tr><tr><td>Refunds<\/td><td>October 6<\/td><\/tr><tr><td>Credit of Shares in Demat a\/c<\/td><td>October 6<\/td><\/tr><tr><td>Listing Date<\/td><td>October 9<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><\/li>\n<\/ul>\n\n\n\n<p>The Valiant Laboratories <a class=\"wpil_keyword_link\" href=\"https:\/\/www.equentis.com\/researchandranking\/ipos\"   title=\"IPO\" data-wpil-keyword-link=\"linked\"  data-wpil-monitor-id=\"972\">IPO<\/a> details are as follows: <\/p>\n\n\n\n<figure class=\"wp-block-table aligncenter is-style-regular\"><table><tbody><tr><td>Total issue size<\/td><td>Rs 152.46 Crores<\/td><\/tr><tr><td>Face Value<\/td><td>Rs 10 per share<\/td><\/tr><tr><td>Fresh issue size<\/td><td>10,890,000 shares<\/td><\/tr><tr><td>Price Band<\/td><td>Rs. 133 -140<\/td><\/tr><tr><td>Lot size<\/td><td>105 shares<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How do you check Valiant Laboratories IPO<\/strong> <strong>allotment status?<\/strong><\/h2>\n\n\n\n<p>You can check your allotment status online if you\u2019ve applied for the Valiant Laboratories IPO. There are two methods to do so:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Option 1: Checking on the BSE Website:<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-image aligncenter is-resized\"><img decoding=\"async\" src=\"https:\/\/lh6.googleusercontent.com\/e4gIjFKrvq1LOuVHS7HjizDcz18mNJL6gYybcsGgLu2u-wUEERhY_lVurYDDEHqVrVMGB9UWyzLo-HzVdbf_9Z0jb_NgpkmQeLRRsSATaHe9YWbedMq8MrQGbumPm2OuANCzDBqQjcq8T74PiYe05ws\" alt=\"\" style=\"width:648px;height:313px\" title=\"\"><figcaption class=\"wp-element-caption\">Source: <a href=\"https:\/\/www.equentis.com\/blog\/explore-bombay-stock-exchange-what-is-bse-advantages-of-listing-and-investment-methods\/\">BSE<\/a><\/figcaption><\/figure>\n\n\n\n<p><a href=\"https:\/\/www.bseindia.com\/investors\/appli_check.aspx\" target=\"_blank\" rel=\"noopener\"><\/a><\/p>\n\n\n\n<p>Visit the BSE IPO allotment page: <a href=\"https:\/\/www.bseindia.com\/investors\/appli_check.aspx\" target=\"_blank\" rel=\"noopener\">BSE IPO Allotment<\/a><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Select \u201cEquity\u201d under \u201cIssue Type.\u201d<\/li>\n\n\n\n<li>Choose \u201cValiant Laboratories Ltd\u201d from the dropdown under \u201cIssue Name.\u201d<\/li>\n\n\n\n<li>Enter your Application Number or PAN.<\/li>\n\n\n\n<li>Complete the CAPTCHA verification.<\/li>\n\n\n\n<li>Click the \u201cSearch\u201d button.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Option 2: Checking on Link Intime India Private Limited\u2019s Website (IPO Registrar):<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-image aligncenter is-resized\"><img decoding=\"async\" src=\"https:\/\/lh5.googleusercontent.com\/4CS3BxBg1895LJ9dichaxW-MmxzxawlkRgsUIaLVOa0VzuMFRyuZwgGVMOD9oIPL8lFSlk3dPszWZJZJ6IPfCX7IZIAfmTrKmeAQ_LVpxtPndbGLFZs9-CfV7xbnkGn8PjtzcxFBOn4a6QKG9pe05YM\" alt=\"\" style=\"width:554px;height:268px\" title=\"\"><figcaption class=\"wp-element-caption\">Source: <strong>IPO Registrar<\/strong> Website<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>When will the basis of allotment for Valiant Laboratories IPO be finalized?<\/strong><\/h2>\n\n\n\n<p>The basis of allotment for Valiant Laboratories Ltd is set to be finalized on October 5, 2023. The company will initiate the refund process on October 6, 2023. You can expect their shares to be credited to their demat accounts on October 6, 2023.<\/p>\n\n\n\n<p>It\u2019s worth noting that the listing of Valiant Laboratories\u2019 stock on the National <a href=\"https:\/\/www.equentis.com\/blog\/reading-stock-charts-the-basics\/\">Stock Exchange<\/a> (<a href=\"https:\/\/www.equentis.com\/blog\/national-stock-exchange-of-india-functions-features-and-top-companies\/\">NSE<\/a>) and the Bombay Stock Exchange (BSE) is scheduled for October 9, 2023.<\/p>\n\n\n\n<p>Further, the stock is expected to list on Monday, October 9, 2023, and given the robust demand and the current grey market premium of +22, investors can anticipate an estimated listing price of \u20b9162 per share, representing a 15.71% premium over the IPO issue price of \u20b9140.<\/p>\n\n\n\n<p>With a strong grey market premium and an estimated listing price, Valiant Laboratories IPO not only reflects the company\u2019s potential but also showcases the enthusiasm of investors to be a part of its journey. As the stock is poised to hit the market on October 9, 2023, we can anticipate an exciting and rewarding chapter ahead for all of you.<\/p>\n\n\n\n<p class=\"has-ast-global-color-5-color has-text-color has-background has-link-color wp-elements-99316fa911e3b5ca7f1cfd997eb788c4\" style=\"background-color:#001e5a\"><strong>Know more about:<br><a href=\"https:\/\/www.equentis.com\/ipos\">IPOs<\/a>&nbsp;|&nbsp;<a href=\"https:\/\/www.equentis.com\/ipos\/current-new-ipos\">Current IPOs<\/a><a href=\"https:\/\/www.equentis.com\/ipos\/current-new-ipos\">&nbsp;<\/a>|&nbsp;<a href=\"https:\/\/www.equentis.com\/ipos\/upcoming-ipos\">Upcoming IPOs <\/a>|&nbsp;<a href=\"https:\/\/www.equentis.com\/ipos\/listed-ipos\">Listed IPO<\/a>s | <a href=\"https:\/\/www.equentis.com\/ipos\/closed-ipos\">Closed IPOs<\/a> | <a data-wpil=\"url\" href=\"https:\/\/www.equentis.com\/ipos\/ipo-performers\">IPO Performers<\/a><\/strong><\/p>\n\n\n\n<p class=\"has-white-color has-vivid-red-background-color has-text-color has-background\">*Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as recommendation or investment advice by&nbsp;Research &amp; Ranking. We will not be liable for any losses that may occur. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by <a href=\"https:\/\/www.equentis.com\/blog\/sebi-registered-investment-advisor-meaning-eligibility\/\">SEBI<\/a>, membership of BASL, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">FAQ<\/h2>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"wp-block-group is-layout-constrained wp-block-group-is-layout-constrained\"><div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list \">\n<div id=\"faq-question-1696403469594\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \"><strong>1. How can I check the Valiant Laboratories IPO allotment status?<\/strong><\/h3>\n<div class=\"rank-math-answer \">\n\n<p>You can check your Valiant Laboratories IPO allotment status online through the BSE website or Link Intime India Private Limited&#8217;s website. Follow the provided steps for each option to check your allotment status.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1696403485507\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \"><strong>2. When will the basis of allotment for Valiant Laboratories IPO be finalized?<\/strong><\/h3>\n<div class=\"rank-math-answer \">\n\n<p>The basis of allotment for Valiant Laboratories IPO will be finalized on October 5, 2023. Refunds will be initiated on October 6, 2023, and shares will be credited to demat accounts on the same day.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1696403502008\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \"><strong>3. What are the key dates for Valiant Laboratories IPO?<\/strong><\/h3>\n<div class=\"rank-math-answer \">\n\n<p>The key dates for Valiant Laboratories IPO are as follows:<\/p>\n<p>Basis of Allotment: October 5, 2023<br \/>Initiation of Refunds: October 6, 2023<br \/>Credit of Shares to Demat: October 6, 2023<br \/>Listing Date: October 9, 2023.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Recently, Valiant Laboratories, a prominent Indian pharmaceutical ingredient manufacturer, made its foray into the world of IPOs. Here is a brief overview of its subscription status, allotment date and more.<\/p>\n","protected":false},"author":5,"featured_media":25858,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[553],"tags":[],"class_list":["post-25853","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing-ipo"],"_links":{"self":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/25853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/comments?post=25853"}],"version-history":[{"count":15,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/25853\/revisions"}],"predecessor-version":[{"id":63075,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/25853\/revisions\/63075"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/media\/25858"}],"wp:attachment":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/media?parent=25853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/categories?post=25853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/tags?post=25853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}